Purpose: We aim to evaluate the efficacy and safety which of sodium glucose co transporter 2(SGLT2)inhibitors on albuminuria in patients with type 2 diabetes mellitus.Patients and methods: We searched three relevant electronic databases(Pub Med,Embase,Web of Science,the Cochrane Library)in order to take in the randomized controlled trials which contained the effect of sodium glucose cotransporter-2 inhibitors for patients with diagnosed type 2 diabetes and complicated with albuminuria.According to the criteria of inclusion and exclusion,the titles and/or abstracts of the retrieved literatures were screened.And the literatures which may be taken in were screened carefully by reading full texts.For the included literature,the quality was evaluated and the basic characteristics of the patients,the design of the studies,the effectiveness and safety of the drug were collected.Result: A total of 7 studies were included for this systematic review,all of them were RCTs with large samples.12 049 patients were analyzed in this system review,and the intervention time was at least 12 weeks.It showed that for patients with type 2 diabetes mellitus with micromacroalbuminuria,empagliflozin compared with placebo,the average difference of albuminuria levels in patients with microalbuminuria and macroalbuminuria was-42%(95% CI,-49 ~-34)and-49%(95% CI,-60 ~-36);100 mg and 300 mg canagliflozin compared with glimepiride,the changes of albuminuria were-31.7%(95% CI,-48.9 ~-8.6),-49.3%(95% CI,-62.2 ~-31.9);different dose of dapagliflozin compared with the control groups,the level of albuminuria was from – 16.1%(95% CI,-32.3-3.8)to-57.2%(95% CI,-77.1-20.1).As for the safety,the incidence of serious adverse which might lead to stopping using the drugs in the intervention group was not significantly higher than the control group.Conclusion: For patients with type 2 diabetes,different doses and kinds of SGLT2 inhibitors have a certain effect on reducing albuminuria of different degrees in diabetic patients and have good safety. |